Loading WGRX detail
Loading ticker data...
Loading WGRX detail
Wellgistics Health, Inc. operates as a wholesaler and distributor of pharmaceutical products to pharmaceutical manufacturers and independent retail pharmacies in the United States.
The company distributes generic and branded pharmaceuticals, as well as over-the-counter healthcare and consumer products. It also offers third-party logistics services that include warehousing, inventory management, pick and pack, and shipping to small and mid-size pharmaceutical manufacturers. It also operates DelivMeds platform that serves as a pharmaceutical hub to facilitate the transfer of prescriptions and provide backend clinical concierge services to a network of independent pharmacies; and operates a retail community specialty. The company was formerly known as Danam Health, Inc. and changed its name to Wellgistics Health, Inc. in October 2024.
Wellgistics Health, Inc. was incorporated in 2022 and is based in Tampa, Florida.
Chart data unavailable
Wellgistics Health is a healthcare technology and pharmaceutical logistics company.
Wellgistics Health, Inc. (NASDAQ: WGRX - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 13th, there was short interest totaling 6,271,116 shares, a growth of 219.6% from the February 26th total of 1,962,253 shares. Based on an average daily volume of 7,921,583 shares,
Despite the positive news, investors are concerned that the acquisition may not be enough to turn around the negative revenue growth Wellgistics experienced in the last year. Revenue fell about half between the last two quarters, going from $7 million to $3 million.
TAMPA, FL / ACCESS Newswire / March 23, 2026 / Wellgistics Health, Inc. ("Wellgistics" or the "Company") (NASDAQ:WGRX) today announced that it has entered into a non-exclusive, non-binding Letter of Intent ("LOI") to evaluate a potential acquisition of Neuritek Therapeutics, a neuroscience-focused research organization. The proposed all stock transaction, if completed, is intended to enhance Wellgistics' existing revenue-generating healthcare platform by expanding capabilities adjacent to its core technology-enabled pharmacy distribution and services business.
TAMPA, FL / ACCESS Newswire / March 19, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ , today announced that its President and Interim Chief Executive Officer, Prashant Patel, together with an additional participant from the Company's Board of Directors, entered into agreements with the Company to convert an aggregate of approximately $2.0 million of accrued compensation into shares of the Company's common stock at a conversion price of $0.20 per share, representing a premium to the Company's recent trading price. In connection with the conversion, the Company will issue approximately 10,000,000 shares of common stock.
TAMPA, FL / ACCESS Newswire / March 13, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that its President & Interim-CEO Prashant Patel, RPh released a letter to shareholders. The prescription drug and broader healthcare landscapes in the United States are rapidly changing.
Medical insurance eligibility and benefits verification (EBV) is a core health technology capability necessary for PharmacyChain™ to gain market adoption EBV services offering enabled with preferred pricing being made immediately available to providers, partners and the Wellgistics Pharmacy Network EBV market expected to grow from $2.39 billion in 2025 to $3 billion in 2030 according to The Business Research Company1 TAMPA, FL / ACCESS Newswire / March 11, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that it has secured contractual rights to preferred pricing for medical insurance eligibility and benefits verification (EBV) that enables PharmacyChain for providers, partners and pharmacies in order to facilitate its faster adoption into the US healthcare ecosystem. EBV is crucial because it allows companies that engage in the distribution of medical products and services to know whether a particular product or service is covered by a patient's insurance carrier and the level of coverage that patient has.
GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301 Proprietary Forzet formulation provides pharmacists, physicians and patients with unique solution for GLP-1 drugs' primary side effect Forzet targeting preservation of muscle while on GLP-1 agonist therapy to facilitate continued patient adherence and muscle redevelopment following therapy discontinuation to help mitigate weight regain TAMPA, FLORIDA / ACCESS Newswire / March 9, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics") , a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ , today announced the launch of medical food Forzet™ for the dietary management of muscle loss associated with weight loss therapies. Forzet is being launched initially to physicians and pharmacists who prescribe and dispense GLP-1 agonist drugs.
Hyperledger Fabric, Ethereum/Polygon, VeChain, Quorum /Besu and Corda (R3) selected as most suitable blockchain platforms to build PharmacyChain™ U.S. prescription drugs market project to grow from $634 billion market to $883 billion by 2030 according to Grandview Research[1] Global blockchain in healthcare market is projected to grow from $11 billion in 2024 to $214 billion by 2030, according to Grandview Research[2] TAMPA, FLORIDA / ACCESS Newswire / March 5, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ , today announced that it has completed its evaluation process to select the most suitable blockchain platforms on which to build smart contracts-enabled pharmaceutical drug tracking system PharmacyChain that will further enable industry-wide serialization mandates, such as the United States' Drug Supply Chain Security Act (DSCSA[3]). The Company selected Hyperledger Fabric, Ethereum/Polygon, VeChain, Quorum/Besu and Corda (R3) as the most suitable blockchain platforms currently in use in order to initiate PharmacyChain development.
Wellgistics Health (NASDAQ: WGRX - Get Free Report) and Summit Therapeutics (NASDAQ: SMMT - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk. Profitability This table compares Wellgistics Health and Summit
Previously announced partnership with Tollo Health subsidiary TolloCare adding telehealth service offering to drive Wellgistics Pharmacy prescription drug dispending of GLP-1 drugs and promote patient engagement via mental health AI software solution for compliance and to promote lifestyle changes TAMPA, FL / ACCESS Newswire / February 18, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (‘AI') platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ , today announced that it has completed a strategic investment in a San Francisco-based mental health AI startup on the cusp of launching its service following successful beta testing. The investment fortifies the Company's strategic partnership with Tollo Health that was expanded to support Wellgistics' partnership with NFL Alumni Health.
Tollo Health recently formed subsidiary TolloCare, LLC ('TolloCare') initially targeted to provide telehealth services for GLP-1 and Long COVID patients TolloCare has white-labeled telehealth capabilities via a telemedicine company with over 5,000 onboarded physicians nationwide to provide synchronous and asynchronous medical services, including prescriptions, for weight loss and separately will cultivate a Long COVD physician base Tollo Health has entered into agreement to expand TolloCare capabilities via a partnership with a stealth San Francisco Bay Area startup preparing to deploy a mental health AI app with unique tools to engage with patients TAMPA, FLORIDA / ACCESS Newswire / February 11, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence ('AI') platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ , today announced that it has expanded its partnership Tollo Health, LLC ('Tollo Health'). The partnership expansion includes the addition of telehealth services being developed by TolloCare, LLC ('TolloCare'), a wholly-owned subsidiary of Tollo Health, which focuses on telemedicine, an app-based mental health AI offering, and public health information.
Wellgistics Health, Inc. (NASDAQ: WGRX - Get Free Report) saw a large decline in short interest in the month of December. As of December 31st, there was short interest totaling 695,222 shares, a decline of 19.7% from the December 15th total of 865,399 shares. Based on an average trading volume of 442,337 shares, the days-to-cover ratio
Feasibility assessment completed, PharmacyChain™ to leverage Datavault AI's edge network and quantum key encryption to improve data driven outcomes in $634 billion prescription drug market Quantum key encryption fortities pharmacies from quantum's pending encryption-busting impact on traditional encryption methods TAMPA, FLORIDA / ACCESS Newswire / January 12, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (‘AI') platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today provided an update on its strategic licensing partnership with DataVault AI, Inc. (NASDAQ:DVLT), a Pioneer in AI-driven data valuation, monetization, and secure tokenization within Web 3.0 environments. Through this partnership, Wellgistics has licensed DataVault AI's advanced technology platform to integrate proprietary blockchain-enabled tokenization and blockchain-enabled smart contract capabilities into its patented PharmacyChain™ platform.
Integration of prescription drug dispensing optimization aritifical intelligence platform EinsteinRx™ into pharmacy client point-of-sales systems has commenced EinsteinRx integration streamlining effort focuses on reducing onboarding process friction and speeding time to implementation prior to scaling pharmacy marketing effort Company expects to onboard up to 500 pharmacies per month into formal Wellgistics Pharmacy Network by year end 2026 Manufacturer supplier relationship expansion effort focused on diabetes, weight loss, cardiometabolic & Long COVID patients that existing pharmacy clients already serve PharmacyChain™ blockchain-enabled healthcare smart contract development resource assessment ongoing TAMPA, FLORIDA / ACCESS Newswire / January 7, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (‘AI') platform EinsteinRx ™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today provided a corporate outlook for 2026 to stakeholders. "Three months following my return to the role of President at Wellgistics, the Company now has a clear direction as we begin a hyper-focused operational execution phase," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health.
